// App-Quantinova.ai

268 : Phase 1/2 trial of cabazitaxel with abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone acetate: Phase 2 results.

Researchers

Presenter

  • Joaquin Mateo

Principal Investigators

  • Karim Fizazi

  • Carmel Jo Pezaro

  • Jenny Zhang

  • Gerhardt Attard

  • Johann Sebastian De Bono

  • Laurence Albiges

  • Diletta Bianchini

  • Andrea Varga

  • Charles J. Ryan

  • Daniel Peter Petrylak

  • Liji Shen

  • Christophe Massard

  • Yohann Loriot

  • Niven Mehra

Medical Centers

  • Sanofi, Cambridge, MA

  • The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United KingdomYale University Medical Center, New Haven, CTUCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

  • The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom

  • Institut Gustave Roussy, University of Paris Sud, Villejuif, France

  • The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom

Locations

  • United States

  • France

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • N/A

Drug/Treatment

  • CB-7598

  • Mitoxantrone

  • Prednisolone

  • Cabazitaxel

  • Prednisone

  • Docetaxel

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I/II

Study Id's

  • N/A

Sponsors

  • Sanofi

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved